These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31305287)

  • 1. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
    Gordon SW; McGuire WP; Shafer DA; Sterling RK; Lee HM; Matherly SC; Roberts JD; Bose P; Tombes MB; Shrader EE; Ryan AA; Kmieciak M; Nguyen T; Deng X; Bandyopadhyay D; Dent P; Poklepovic AS
    Am J Clin Oncol; 2019 Aug; 42(8):649-654. PubMed ID: 31305287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
    El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
    Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
    Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
    Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
    Ikeda M; Morimoto M; Tajimi M; Inoue K; Benhadji KA; Lahn MMF; Sakai D
    Invest New Drugs; 2019 Feb; 37(1):118-126. PubMed ID: 29995286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
    Tran NH; Foster NR; Mahipal A; Byrne T; Hubbard J; Silva A; Mody K; Alberts S; Borad MJ
    Invest New Drugs; 2021 Aug; 39(4):1072-1080. PubMed ID: 33646489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
    Molina AM; van der Mijn JC; Christos P; Wright J; Thomas C; Dutcher JP; Nanus DM; Tagawa ST; Gudas LJ
    Invest New Drugs; 2020 Oct; 38(5):1383-1389. PubMed ID: 31898184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
    Ishizaki M; Kaibori M; Matsui K; Ikeda H; Yoshida K; Okazaki K; Kariya S; Tanigawa N; Nakatake R; Matsushima H; Sakaguchi T; Kon M
    Cancer Invest; 2017 Apr; 35(4):271-276. PubMed ID: 28272913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
    Duffy AG; Ma C; Ulahannan SV; Rahma OE; Makarova-Rusher O; Cao L; Yu Y; Kleiner DE; Trepel J; Lee MJ; Tomita Y; Steinberg SM; Heller T; Turkbey B; Choyke PL; Peer CJ; Figg WD; Wood BJ; Greten TF
    Clin Cancer Res; 2017 Aug; 23(16):4633-4641. PubMed ID: 28465443
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
    Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
    J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Sho T; Nakanishi M; Morikawa K; Ohara M; Kawagishi N; Izumi T; Umemura M; Ito J; Nakai M; Suda G; Ogawa K; Chuma M; Meguro T; Nakamura M; Nagasaka A; Horimoto H; Yamamoto Y; Sakamoto N
    Drugs R D; 2017 Sep; 17(3):381-388. PubMed ID: 28573606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study).
    Keino D; Yokosuka T; Hirose A; Sakurai Y; Nakamura W; Fujita S; Hayashi A; Miyagawa N; Iwasaki F; Hamanoue S; Yanagimachi M; Shiomi M; Goto S; Kitagawa N; Tanaka M; Nozawa K; Tanaka Y; Goto H
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28655. PubMed ID: 32798298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
    Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
    Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
    Petrini I; Lencioni M; Ricasoli M; Iannopollo M; Orlandini C; Oliveri F; Bartolozzi C; Ricci S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):773-80. PubMed ID: 22033636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.